Insilico nominates peripheral VAV1 molecular glue degrader ISM9546
Company / institutional announcement · Insilico Medicine
Source published:
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
Insilico Medicine nominated ISM9546 as a preclinical candidate for autoimmune diseases, including inflammatory bowel disease and rheumatoid arthritis. The company described an orally available, peripherally restricted VAV1 molecular glue degrader, reporting cellular degradation activity and anti-inflammatory effects in disease models. Its limited brain exposure is a design feature; human safety and efficacy have not been established.
Why it may matter
A new VAV1 entrant could sharpen competition around selectivity and tissue exposure, but animal findings still require clinical translation and validation.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections